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Retromer is a complex of proteins that functions in the endosome-to-Golgi retrieval cargo transport
pathway. VPS35 works as the central subunit of retromer to recognize the cargos and binds with
VPS29 and VPS26 via distinct domains. We show that deﬁciency of VPS35 or VPS29 accompanies
degradation of other subunits, whereas VPS26 deﬁciency had no effect on VPS29 and VPS35 levels.
Although VPS35 forms VPS26–VPS35 and VPS29–VPS35 sub-complexes with similar efﬁciency
in vitro, VPS26–VPS35 was more easily degradable by the ubiquitin–proteasome-system than
VPS29–VPS35. These results indicate that VPS29 and VPS35 form a biologically stable sub-complex
in vivo.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction endosome to trans-Golgi-network (TGN) [1,2]. Initially, subunitsRetromer is an evolutionarily conserved protein complex that
functions in the retrieval transport of cargo proteins from theof the retromer complex were identiﬁed as components of the sort-
ing machinery required for the endosome-to-Golgi retrieval of the
carboxypeptidase Y receptor VPS10 in Saccharomyces cerevisiae [3].
The components of retromer are highly conserved from yeast to
mammals and consist of cargo-recognition sub-complexes con-
taining VPS35, VPS29, VPS26, and sorting nexin (SNX) dimers of
SNX1 and SNX2 (and possibly SNX5 and SNX6) [2,4,5]. These two
sub-complexes assemble into a multimeric membrane coat in
endosomes. VPS35, the largest subunit of retromer, acts as the cen-
ter of the cargo-recognition complex to independently interact
with VPS26 and VPS29 in retromer, and interact with cargos, i.e.,
cation-independent mannose 6-phosphate receptor (CI-M6PR),
Wntless, and DMT1 [2,6,7]. VPS26 has structural similarity with
arrestin, a trafﬁcking adaptor protein [8]. VPS29 has a phophoes-
terase fold and works as a scaffold for retromer assembly [9,10].
VPS35 binds with VPS26 via N-terminal PRLYL motif, and with
VPS29 via C-terminal region, and can form sub-complexes with
either of them in vitro [11–13]. CI-M6PR, which functions as a
A. Fuse et al. / FEBS Letters 589 (2015) 1430–1436 1431lysosomal enzyme receptor, is one of the representative cargos of
retromer [2]. Upon dissociation of CI-M6PR from its ligands in
endosomes, CI-M6PR is transported back to TGN via the retromer
complex through interaction between the C-terminal cytoplasmic
domain of CI-M6PR and the VPS35 subunit [14]. In addition to ret-
romer components and cargos, VPS35 interacts with the
GTP-bound form of Rab7 via N-terminal conserved region of
VPS35, and the retromer is consequently recruited to the endo-
some via this interaction [15].
Recently, a number of reports revealed that a point mutation in
the VPS35 gene (D620N) causes late-onset, autosomal dominant
Parkinson’s disease [16–18]. The mutant form of VPS35 causes
defects in cathepsin D trafﬁcking [19] and alters association with
the actin-nucleating Wiskott-Aldrich syndrome and SCAR homolog
(WASH) complex [20,21]. These molecular-based studies suggest
that VPS35 D620N induces a loss-of-function pathogenesis.
We performed knockdown of retromer components using
siRNA to elucidate the differences of retromer component deﬁ-
ciency. We found that in the absence of VPS29 expression, the
VPS26–VPS35 sub-complex is very fragile and easily ubiquitylated
and degraded by proteasomes. This ﬁnding indicates that VPS29–
VPS35 dimer formation may be the initial step of retromer assem-
bly in vivo.
2. Materials and methods
2.1. Plasmid DNA construction
Human VPS35, VPS35 D620N, VPS29, VPS26A, and mCherry
were cloned by PCR using VPS35 expression plasmids, cDNA of
HeLa cell or pmCherry vector as templates. VPS35 wild-type or
mutants, and mCherry were ligated into pcDNA3.1-Hyg (+) vector
(Life Technologies, Carlsbad, CA, USA) to construct N-terminal
mCherry-tagged VPS35 expression plasmids. VPS29 or VPS26A
were cloned into p3xFLAG-CMV-7.1 or p3xFLAG-CMV-14 vectors
(Sigma–Aldrich, St. Louis, MO, USA) for N-terminal FLAG-tagged
or C-terminal FLAG-tagged fusion protein expression, respectively.
2.2. Cell culture and transfection
HeLa cells were maintained in Dulbecco’s Modiﬁed Eagle
Medium supplemented with 10% fetal bovine serum and 100
units/mL penicillin/streptomycin in a humidiﬁed 37 C incubator
supplemented with 5% CO2/95% O2. Plasmid DNAs were transfected
into cells using Lipofectamine 2000 Reagent (Life Technologies)
according to the manufacturer’s protocol. For RNA interference
experiments, ON-TARGETplus human siRNA oligos (Thermo
Scientiﬁc Dharmacon, Waltham, MA, USA; GE Dharmacon,
Lafayette, CO, USA) for VPS35 (L-010894-00-0005), VPS29
(L-009764-01-0005), VPS26A (L-013195-00-0005), VPS26B
(L-015152-00-0005), SNX1 (L-017518-00-0005), SNX2
(L-017520-00-0005), and scrambled siRNA (D-001810-10-20) were
transfected into cells using Lipofectamine RNAiMAX Reagent (Life
Technologies) according to the manufacturer’s instructions.
2.3. Antibodies and reagents
Anti-VPS35 (NB100-1397, Novus Biologicals, Littleton, CO, USA)
antibodies were obtained from Novus Biologicals. Anti-VPS29
(ab98929), anti-VPS26 (ab181352), and anti-cation independent
Mannose 6 Phosphatase Receptor antibodies (ab2733, ab124767)
were from Abcam (Cambridge, UK). Anti-SNX1 (611482),
anti-SNX2 (611308), and anti-EEA1 antibodies (610457) were from
BD Transduction Laboratories (San Jose, CA, USA). The anti-TGN46
antibody (T7576) was from Sigma–Aldrich. The anti-EEA1 antibody(2411), and anti-LC3B antibody (3868) were from Cell Signaling
Technology (Boston, MA, USA). The anti-Cathepsin D antibody
(sc6486) was from Santa Cruz Biotechnology (Dallas, Texas, USA).
The anti-Actin antibody (MAB1501R) was from Millipore
(Billerica, MA, USA). Anti-RFP (M208-3) and anti-Multi
Ubiquitin antibodies (D058-3) were obtained from Medical &
Biological Laboratories Co. Ltd. (Nagoya, Japan). Alexa Fluor
488-conjugd, Alexa Fluor 594-conjugated, and horseradish
peroxidase-conjugated secondary antibodies were from Jackson
ImmunoResearch Laboratories, Inc. Pepstatin A (4397-v), E-64-d
(4321-v), and MG-132 (aldehyde, 3175-v) were purchased from
Peptide Institute, Inc. (Osaka, Japan).
2.4. Western blotting
Cells were lysed in RIPA buffer (150 mM NaCl, 50 mM Tris–HCl
pH 8.0, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dode-
cyl sulfate) containing a protease inhibitor cocktail (Roche
Diagnostics, Mannhelm, Germany, 11873580001) and the
14,000g supernatants were used as cell lysates. Cell lysates and
immunoprecipitants were resolved by SDS–PAGE and transferred
onto PVDF membranes. The blots were incubated with primary
antibodies followed by HRP-conjugated secondary antibodies. For
detection, ECL prime Detection Kit (GE Healthcare, Little
Chalfont, UK, RPN2232) or SuperSignal West Dura Extended
Substrate (Thermo Scientiﬁc, Rockford, IL, USA, 34075) were used
as chemiluminescent substrates and images were analyzed using
LAS4000 mini (GE Healthcare).
2.5. Quantitative real-time PCR analysis
mRNA was isolated using TRIzol reagent (Invitrogen,
15596026). cDNA was prepared using the ReverTra Ace qPCR RT
Master Mix (TOYOBO Co. Ltd., Osaka, Japan, FSQ-201) according
to the manufacturer’s protocol. Quantitative real-time PCR was
performed using the 7500 Fast Real-Time PCR Systems (Applied
Biosystems, Foster City, CA, USA) and the Fast SYBR Green Master
Mix (Life Technologies, 4385612) according to the manufacturer’s
instructions.
2.6. Immunoprecipitation
For siRNA-treated cells, cells expressed mCherry-VPS35,
mCherry-VPS35 D620N, N-terminal or C-terminal FLAG-tagged
VPS29 or N-terminal or C-terminal FLAG-tagged VPS26A at 24 h
after siRNA transfection. Forty-eight hours after plasmid transfec-
tion, cells were lysed in NP-40 lysis buffer (50 mM Tris–HCl,
150 mM NaCl, 1 mM EDTA and 1% NP-40) containing protease
and phosphatase inhibitor cocktail (Roche Diagnostics,
11873580001; 04906837001) for 10 min on ice. The 14,000g
supernatants were incubated with anti-RFP mAb magnetic beads
(MBL, M165-9) or the anti-FLAG antibody followed by Dynabeads
protein G-Sepharose (Life Technologies, 10004D).
2.7. Immunoﬂuorescence staining
Cells grown on glass-chamber slides were transfected with
siRNAs. Forty-eight hours after transfection, cells were ﬁxed with
4% paraformaldehyde. To detect intracellular localization of
VPS35, CI-M6PR, EEA1, and TGN46, cells were incubated with pri-
mary antibodies followed by Alexa Fluor 488- or Alexa Fluor
594-conjugated secondary antibodies. Fluorescence staining was
visualized using an Olympus FV1000 confocal microscope. For
the quantiﬁcation of colocalization of CI-M6PR with EEA1 or
TGN46, the colocalization area of CI-M6PR with EEA1 or TGN46
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Fig. 1. Knockdown of VPS35 inﬂuences the maturation of cathepsin D and the trafﬁcking of CI-M6PR. (a) Western blotting analysis of VPS35 knockdown cells. HeLa cells
transfected with siVPS35 or scrambled siRNA were harvested at 12–72 h after transfection. Cell lysates were subjected to Western blotting using anti-VPS35, anti-cathepsin
D, and anti-actin (as a loading control) antibodies. (b) Localization of CI-M6PR, EEA1, and TGN46 in the VPS35 knockdown cells. VPS35 knockdown cells were stained with
antibodies against EEA1, TGN46, and CI-M6PR. Scale bar, 10 lm. (c and d) Quantitative analysis of colocalization of CI-M6PR with EEA1 (c) or TGN46 (d) shown in (b).
*P < 0.05. (e) Electron micrographs of VPS35 knockdown cells. Arrow, endosome-lysosome-like vesicles; scale bar, 0.5 lm.
1432 A. Fuse et al. / FEBS Letters 589 (2015) 1430–1436were quantiﬁed using a set of single confocal images by image cal-
culator of imageJ software. Percentages of colocalization were
determined by calculation of the colocalization area over total
CI-M6PR area.
2.8. Electron microscopy
Cells were ﬁxed with 2.5% glutaraldehyde in 0.1 M phosphate
buffer (pH 7.4) for 2 h, and post-ﬁxed in 1% osmium tetroxide in
0.1 M phosphate buffer for 1 h. Fixed cells were dehydrated and
embedded in Epon 812. Ultrathin sections were stained with ura-
nyl acetate and lead citrate, and observed using a Hitachi
HT7700 transmission electron microscope.
2.9. Statistics
All data are expressed as means ± S.D. Differences between
groups were examined for statistical signiﬁcance using Student t
test. A P value < 0.05 was considered statistically signiﬁcant.
3. Results and discussion
3.1. Knockdown of VPS35 impairs not only retrograde transport but
also anterograde transport of CI-M6PR
To assess the function of the endosome-to-Golgi retrograde
transport, we knocked down VPS35 using a speciﬁc siRNA oligo
for human VPS35 in HeLa cells (Fig. 1). To optimize the experimen-
tal condition, cells were harvested at 12 h, 24 h, 48 h, and 72 h after
siRNA transfection (Fig. 1a). Expression levels of VPS35 were dra-
matically decreased and reached their lowest level 48 h aftertransfection and maintained this level until 72 h after transfection.
Therefore, we decided to use knockdown in cells 48–72 h after
transfection.
In control cells, CI-M6PR localized to both endosomes and
trans-Golgi at perinuclear regions (with EEA1: 11.6% and with
TGN46: 15.5%, Fig. 1b–d). In VPS35 knockdown cells, CI-M6PR
was signiﬁcantly enriched at trans-Golgi, while its localization to
endosomes was not altered (colocalization with TGN46: 21.4%
and with EEA1: 14.3%). The distribution of CI-M6PR indicates that
VPS35 knockdown induces a defect in the shuttling of CI-M6PR
resulting in an accumulation in the trans-Golgi. However, we
expected CI-M6PR accumulation at endosome rather than
trans-Golgi by VPS35 knockdown, because of retromer functions
retrograde transport from endosome to trans-Golgi. It has been
previously reported that knockdown of VPS35 induces the
mis-sorting of DMT1, a cargo of retromer to lysosome [6] and the
accumulation of Cathepsin D precursor form, a ligand of CI-M6PR
[19,22]. Cathepsin D is synthesized as an inactive precursor and
becomes a mature active form in the lysosome. Thus, VPS35 knock-
down inﬂuences not only the retrograde vesicular transport path-
way, but also anterograde transport pathway. In VPS35 knockdown
cells, we also observed an accumulation of the precursor form of
Cathepsin D, while the levels of the mature form were comparable
(Fig. 1a). These results indicate that only the transport of de nove
synthesized Cathepsin D was inﬂuenced by VPS35 knockdown in
our study. On the other hand, Cathepsin D existing at endosomes
might be probably transported to lysosomes and became
mature-form. CI-M6PR existing at endosome might also be trans-
ported to lysosome and degraded, and apparently showed the
accumulation in trans-Golgi. Electron microscopy analysis revealed
that abnormal endosome-lysosome-like vesicles accumulated in
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phenotypes indicate that VPS35 knockdown induced the defect
of intracellular trafﬁcking of CI-M6PR.
3.2. Knockdown of VPS35 and VPS29, but not of VPS26, reduces the
levels of its binding partners
Interestingly, we found that the levels of VPS26A were signiﬁ-
cantly reduced and the levels of VPS29 were slightly reduced by
VPS35 knockdown (Fig. 2a). However, levels of SNX1 and SNX2,
further components of the retromer, were not affected by VPS35
knockdown. VPS35 acts as a central subunit of the VPS26–
VPS29–VPS35 hetero-trimeric complex. It is possible that without
formation of the trimeric complex with VPS35, VPS26 and VPS29
subunits are intrinsically fragile proteins. We examined the effects
of VPS26A and VPS29 knockdown using speciﬁc siRNA on the
levels of retromer components. The levels of VPS26A and VPS35
were signiﬁcantly reduced in VPS29 knockdown cells. However,
VPS26A knockdown had almost no effects on VPS29 and VPS35
levels. In addition, knockdown of SNX1 and SNX2, the other retro-
mer complex components, also had no effects on VPS26A, VPS29,
and VPS35 levels. Because SNXs are recruited to the endosomeFig. 2. Knockdown of VPS35 and VPS29 accompany the reduction in the levels of
binding partners by proteasomes. (a) Western blotting of cells knocked down
VPS35, VPS29, VPS26A, SNX1, or SNX2. Cells transfected with siVPS35, siVPS29,
siVPS26A, siSNX1, siSNX2, and scrambled siRNA were analyzed by Western blotting
with indicated antibodies. (b) Western blotting of VPS26A and/or VPS26b knock-
down cells. Cells knocked down VPS26A and/or VPS26B were subjected to Western
blotting of VPS35, VPS29, and VPS26A. (c) Quantiﬁcation of VPS26B mRNA levels in
VPS26A and/or VPS26B knockdown cells by quantitative real-time PCR. ***P < 0.001;
NS: not signiﬁcant. (d) Western blotting of retromer subunits knockdown cells in
the presence and absence of lysosomal or proteasomal inhibitors. Cells transfected
with siRNA for retromer components were incubated with or without Pepstatin A
(10 lg/mL) plus E-64d (10 lg/mL) and MG-132 (10 lM) for 24 h.independently of the VPS26–VPS29–VPS35 complex [23], SNXs
may not have an effect on the stability of cargo-recognition com-
plex components.
There are two paralogs of VPS26 that exist in mammalian cells,
VPS26A and VPS26B [24]. VPS26B is found in the cytoplasm with
low levels at the plasmamembrane,while VPS26A is predominantly
associated with endosomal membranes in HeLa cells [24]. The dif-
ference in phenotypes observed between knockdown of VPS26A
and of the other two subunits may be caused by the existence of
another VPS26 paralog, VPS26B. We therefore tested knockdown
of VPS26B using a speciﬁc oligo for VPS26B (Fig. 2b and c). Similar
to VPS26A knockdown, VPS26B knockdown did not inﬂuence the
levels of VPS29 and VPS35. In addition, the levels of VPS29 and
VPS35 were not signiﬁcantly reduced in VPS26A and VPS26B
double-knockdown cells. These results indicate that expression
levels of VPS29 and VPS35 inﬂuence the levels of the other subunit
of cargo-recognition complex, but VPS26 does not.
To clarify which protein degradation system participates in the
degradation of retromer components in knockdown cells, we
examined the effect of proteasome and lysosome inhibitors in each
knockdown condition. The degradation of VPS35 in VPS29 knock-
down cells, and VPS26A in VPS29 or VPS35 knockdown cells were
inhibited by MG-132, a proteasome inhibitor, but not inhibited by
pepstatin A plus E64d, a lysosome inhibitor cocktail (Fig. 2d) [25].
LC-3-II, an autophagosomal marker protein, was accumulated by
both pepstatin A plus E64d treatment and MG-132 treatment.
MG-132 inhibits not only proteasome but also inhibit certain lyso-
somal hydrolases such as cathepsins [25]. However, neither of
these inhibitors affected the levels of VPS29 in VPS26 or VPS35
knockdown cells. It is possible that another protein degradation
system is involved in the degradation of VPS29 in VPS26 or
VPS35 knockdown conditions. These results indicate that VPS26
and VPS35 can easily be degraded by the proteasome in VPS29
knockdown cells.
3.3. VPS29 and VPS35 stably form an intermediate sub-complex of the
retromer
Using isothermal titration calorimetry, Norwood and her col-
leagues reported that in vitro interactions of VPS35 with VPS29
and VPS26 are independent of each other [26]. However, it is pos-
sible that VPS26–VPS35 and VPS29–VPS35 are biologically differ-
ent in stability, even if the efﬁciency of the sub-complex
formation is comparable. To conﬁrm whether the difference of
effects by VPS29 or VPS35, and VPS26 knockdown on
levels of binding partners are caused by the stability of
sub-complexes, we performed immunoprecipitation experiments.
mCherry-VPS35-, FLAG-VPS29-, and FLAG-VPS26A-expressing cells
were used to detect intermediate sub-complexes of the retromer
directly with knockdown of their binding partners (Fig. 3).
N-terminal tagging of VPS35 does not interfere with the protein
function in protein–protein interaction studies described previ-
ously [20], while there are a few reports about tagged VPS26A
and VPS29. To overcome the steric hindrances by N-terminal or
C-terminal FLAG-tag for protein–protein interactions, we used
both N-terminal and C-terminal tagged VPS29 and VPS26A in this
study. Although the expression levels of mCherry-VPS35 were also
reduced by VPS29 knockdown, VPS26A knockdown did not have
an obvious effect on mCherry-VPS35 (Fig. 3a). Similar to
mCherry-VPS35 expression, VPS29 knockdown reduced
co-immunoprecipitation of mCherry-VPS35 and VPS26A, whereas
VPS26A knockdown did not inﬂuence co-immunoprecipitation of
mCherry-VPS35 and VPS29. In addition, Parkinson’s disease linked
mutation (D620N) of VPS35 did not show any difference with
wild-type interaction with VPS29 or VPS26A in VPS26A knock-
down or VPS29 knockdown cells, respectively. These results are
Fig. 3. VPS29 and VPS35 forms stable intermediate sub-complex without VPS26A expression. (a–c) Western blotting of immunoprecipitants from cells expressing retromer
components. mCherry-VPS35, mCherry-VPS35 D620N mutant (a), N- or C-terminal FLAG-VPS29 (b), or N- or C-terminal FLAG-VPS26 (c) were expressed in cells knocked
down with siRNA for VPS35, VPS29, or VPS26A. Cell lysates were applied to immunoprecipitation with anti-RFP or anti-FLAG.
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C-terminal FLAG-tagged VPS29 and N-terminal FLAG-tagged
VPS26A were much higher than N-terminal FLAG-VPS29 and
C-terminal FLAG-VPS26A (Fig. 3b and c). The levels of immunopre-
cipitated binding partners were comparable with each other in
scramble siRNA transfected cells. Therefore, expression levels of
N-terminal FLAG-VPS29 and C-terminal FLAG-VPS26A seemed to
be efﬁcient to interact with endogenous binding partners, and both
N- and C-terminal FLAG-tag did not cause steric hindrances for ret-
romer formation. In addition, levels of both FLAG-VPS29 and
FLAG-VPS26A were not inﬂuenced by knockdown of their binding
partners. However, VPS29 knockdown signiﬁcantly decreased
VPS35 levels in FLAG-VPS26A immunoprecipitants (Fig. 3c), whileVPS26A knockdown had no effect on VPS35 levels in FLAG-VPS29
immunoprecipitants (Fig. 3b). These results suggest that VPS35
forms two different intermediate dimers with VPS29 or VPS26,
and the levels of VPS26A-VPS35 dimers are easily affected by
VPS29 expression than VPS29–VPS35 is by VPS26A expression.
3.4. VPS26–VPS35 sub-complex is easily ubiquitylated in vivo
VPS26 and VPS35 are degraded by proteasomes in VPS29
knockdown cells (Fig. 2c). It is possible that the interaction with
VPS29 determines the stability of the other two subunits. To con-
ﬁrm the hypothesis, we investigated ubiquitylation levels of
mCherry-tagged VPS35 immunoprecipitants in VPS29 or VPS26A
Fig. 4. The loss of VPS29 interaction induces poly-ubiquitylation of sub-complexes
containing VPS35. Western blotting of anti-RFP immunoprecipitants (b) and their
inputs (a) from cells expressing mCherry-tagged VPS35 constructs. Cells knocked
down with siRNA for VPS29 or VPS26A, were expressed mCherry-VPS35 and
incubated with or without 10 lM MG-132 for 24 h. Cell lysates were immunopre-
cipitated with anti-RFP antibody.
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polyubiquitylation of mCherry-VPS35 immunoprecipitants
between all conditions in the absence of MG-132. However, more
polyubiquitylation of mCherry-VPS35 immunoprecipitant was
detected in immunoprecipitants from VPS29 knockdown cells than
the others in the presence of MG-132. These results indicate that
VPS26–VPS35 sub-complex can be easily ubiquitylated and
degraded by proteasome compared with the VPS29–VPS35 dimer
or VPS26–VPS29–VPS35 trimer. VPS29 acts as a scaffold protein
in cargo-recognition complex assembly and localizes to endosomes
by binding with VPS35 [9,10]. In addition, SNX1 interacts with a
groove on VPS29 on the face distal to VPS35, and with two different
sites on the N- and C-terminal of VPS35[12]. Therefore, interaction
between VPS29 and VPS35 is intrinsically important for retromer
assembly. However, mutation of VPS35 at arginine 107 in the
PRLYL motif, which is the VPS26 binding site, results in loss of
co-localization with Rab7 [15]. As Rab7 plays a role for retromer
recruitment to endosome, interaction between VPS26 and VPS35
is important for the localization of retromer on endosomes. It is
possible that the VPS26–VPS35 sub-complex is able to compete
with the VPS26–VPS29–VPS35 trimer in localization on endosomes
via interaction with Rab7. To avoid the competition, in the absence
of VPS29 interaction, the VPS26–VPS35 sub-complex may be
immediately removed by the ubiquitin–proteasome system.
Therefore, even if the efﬁciency of VPS29–VPS35 and VPS26–
VPS35 sub-complex formation is comparable in vitro [26], the
VPS29–VPS35 sub-complex can be regarded as an initial
sub-complex in retromer complex assembly in vivo.
Together, VPS29–VPS35 sub-complex formation is thought to
be the initial step of retromer assembly process in vivo, and the
loss of VPS29 or VPS35 reduces the stability of the other compo-
nents of the cargo-recognition complex of retromer.
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